161
Views
3
CrossRef citations to date
0
Altmetric
Short Communication

Effect of Nabiximols On Goal Attainment Scale Scores in Patients With treatment-resistant Multiple Sclerosis Spasticity

ORCID Icon & ORCID Icon
Pages 143-153 | Received 17 Nov 2020, Accepted 11 Feb 2021, Published online: 01 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Andrew Chan & Carlos Vila Silván. (2022) Evidence-based Management of Multiple Sclerosis Spasticity With Nabiximols Oromucosal Spray in Clinical Practice: A 10-year Recap. Neurodegenerative Disease Management 12:3, pages 141-154.
Read now

Articles from other publishers (2)

Michael R Haupts, Ute Essner & Mathias Mäurer. (2024) Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative Disease Management.
Crossref
Pavel Loeza Magaña. (2023) Sección IV: Tratamiento sintomático en esclerosis múltiple<br>Capítulo 1<br>Déficit motor y espasticidad. Neurología, Neurocirugía y Psiquiatría 51:2, pages 93-94.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.